Innovations in Blood Cancer Treatment: Navigating CAR T-cell and Bispecific Therapies

Click Here to Participate

Recorded on: April 10, 2025
1.5 CE Credit/Contact hours for nurses and social workers available until: December 18, 2026
1.5 CE Contact hours for nurse practitioners available until: June 30, 2026
ILNA Accredited
Format: Non-interactive recorded webinar

Target Audience

This CE activity is intended for oncology nurses, social workers and nurse practitioners involved in the care of patients with hematologic malignancies.

Description

This recorded webinar is derived from ONS Congress 2025. Earn free CE credit, as you deepen your expertise on the availability and application of CAR T-cell and bispecific therapies to treat patients with hematologic malignancies. Learn about treatment protocols and procedures, identifying and managing common adverse events, and management of bispecific therapy in the community.

Broaden your understanding of the newest treatments, safety and efficacy, patient management, disparities in care, resources for patient education and support from The Leukemia & Lymphoma Society, and more in this interactive session, to improve patient care!

Educational Objectives

Upon completion, participants should be better able to:

• Describe the principles and mechanisms of CAR T- cell and bispecific therapies in treating blood cancers
• Identify clinical indications, including recent FDA approvals and therapies in clinical trials, and disparities in care
• Explain treatment protocols, including pre-treatment conditioning, infusion procedures, identifying and managing common adverse events, management of bispecific therapy in the community, and strategies to improve patient-centered care
• Assess the efficacy of CAR T-cell and bispecific therapies to make informed decisions about treatment options
• List resources and education to support patients, caregivers, and healthcare professionals

Faculty

Tara M Graff, DO, MS
Medical Oncologist
Director of Clinical Trials 
Mission Cancer and Blood/UIHSMG
Director of Cellular Therapy 
ONCare Alliance
Des Moines, IA

Jonathan Gutman, MD
Director of Cellular Therapies 
Professor, Medicine-Hematology
University of Colorado 
Aurora, CO

Michelle McDaniel, RN, CIONS President
Mission Cancer
Des Moines, IA

Samantha Schad, MSN, RN, OCN, WTA-C
Oncology Clinical Practice Leader
Hospital of the University of Pennsylvania
Philadelphia, PA

Continuing Education Information

Nursing Continuing Professional Development Contact Hours
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing. 

Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 25057236. This activity was planned in accordance with AANP Accreditation Standards and Policies.

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON AOCNP) 1.0*, Foundations of Transplant (BMTCN) 1.0*, Oncologic Emergencies (OCN, CPHON, AOCNP) 1.0*, Oncology Nursing Practice (OCN) 1.0*, Professional Practice /Performance (BMTCN, AOCNP) 0.5*, Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN) 0.5*, Quality of Life (BMTCN) 0.5*, Roles of the APRN (AOCNP) 0.5*, Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) 1.0*, Transplant Process and Infusion (BMTCN) 1.0*, Treatment (OCN, CBCN, AOCNP, CPHON) 1.5*.
Total points: 1.5
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum amount of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Provider
This activity is provided by The Leukemia & Lymphoma Society.  

Support
This activity is supported by Autolus Therapeutics.
 

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.